Metabolically stable tert-butyl replacement

ACS Medicinal Chemistry Letters

Volumn 4, Issue 6, 2013, Pages 514-516

  Barnes Seeman, David ^a   Jain, Monish ^a   Bell, Leslie ^a   Ferreira, Suzie ^a   Cohen, Scott ^a   Chen, Xiao Hui ^a   Amin, Jakal ^a   Snodgrass, Brad ^a   Hatsis, Panos ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Clearance; Metabolic stability; Metabolism; T butyl; Tert butyl; Tertiary butyl

Indexed keywords

CYCLOPROPANE DERIVATIVE; FINASTERIDE; METHYL GROUP;

AEROBIC METABOLISM; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG TRANSFORMATION; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84879106746     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400045j     Document Type: Article

References (19)

1. Lau, Y. Y.; Krishna, G.; Yumibe, N. P.; Grotz, D. E.; Sapidou, E.; Norton, L.; Chu, I.; Chen, C.; Soares, A. D.; Lin, C. C. The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios. Pharm. Res. 2002, 19 (11), 1606-1610.
2. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27 (11), 1350-1359.
3. Guengerich, F. P. Cytochrome P450 and Chemical Toxicology. Chem. Res. Toxicol. 2008, 21 (1), 70-83.
4. Lu, A. Y.; Wang, R. W.; Lin, J. H. Cytochrome P450 in vitro reaction phenotyping: A re-evaluation of approaches used for P450 isoform identification. Drug Metab. Dispos. 2003, 31 (4), 345-350.
5. Wuitschik, G.; Carreira, E. M.; Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Muller, K. Oxetanes in drug discovery: structural and synthetic insights. J. Med. Chem. 2010, 53 (8), 3227-3246.
6. Wuitschik, G.; Rogers-Evans, M.; Buckl, A.; Bernasconi, M.; Marki, M.; Godel, T.; Fischer, H.; Wagner, G.; Parrilla, I.; Schuler, F.; Schneider, J.; Alker, A.; Schweizer, W. B.; Muller, K.; Carreira, E. M. Spirocyclic oxetanes: synthesis and properties. Angew. Chem., Int. Ed. 2008, 47 (24), 4512-4515.
7. Wuitschik, G.; Carreira, E. M.; Rogers-Evans, M.; Muller, K. Oxetan-3-one: chemistry and synthesis. Process Chem. Pharm. Ind. 2008, 217-229.
8. Wuitschik, G.; Rogers-Evans, M.; Muller, K.; Fischer, H.; Wagner, B.; Schuler, F.; Polonnchuk, L.; Carreira, E. M. Oxetanes as promising modules in drug discovery. Angew. Chem., Int. Ed. 2006, 45 (46), 7736-7739.
9. In vitro potency comparisons have been published for compounds containing either tert-butyl or Cp-CF3 (refs 9-11). To the best of our knowledge, there are no reports of using the Cp-CF3 group to increase metabolic stability compared to tert-butyl: Paone, D. V.; Nguyen, D. N.; Shaw, A. W.; Burgey, C. S.; Potteiger, C. M.; Deng, J. Z.; Mosser, S. D.; Salvatore, C. A.; Yu, S.; Roller, S.; Kane, S. A.; Selnick, H. G.; Vacca, J. P.; Williams, T. M. Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918. Bioorg. Med. Chem. Lett. 2011, 21 (9), 2683-2686.
10. Lee, S. H.; Seo, H. J.; Lee, S.-H.; Jung, M. E.; Park, J.-H.; Park, H.-J.; Yoo, J.; Yun, H.; Na, J.; Kang, S. Y.; Song, K.-S.; Kim, M.-a.; Chang, C.-H.; Kim, J.; Lee, J. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. J. Med. Chem. 2008, 51 (22), 7216-7233.
11. Phillips, D. J.; Davenport, R. J.; Demaude, T. A.; Galleway, F. P.; Jones, M. W.; Knerr, L.; Perry, B. G.; Ratcliffe, A. J. Imidazopyridines as VLA-4 integrin antagonists . Bioorg. Med. Chem. Lett. 2008, 18 (14), 4146-4149.
12. Lundahl, A.; Lennernäs, H.; Knutson, L.; Bondesson, U.; Hedeland, M. Identification of finasteride metabolites in human bile and urine by high-performance liquid chromatography/tandem mass spectrometry. Drug Metab. Dispos. 2009, 37 (10), 2008.
13. Hulin-Curtis, S. L.; Petit, D.; Figg, W. D.; Hsing, A. W.; Reichardt, J. K. V. Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncol. 2010, 6 (12), 1897.
14. For an example, where a site other than tert-butyl was the primary site of metabolism, replacing the tert-butyl with Cp-CF3 did not improve clearance: Guo, C.; McAlpine, I.; Zhang, J.; Knighton, D. D.; Kephart, S.; Johnson, M. C.; Li, H.; Bouzida, D.; Yang, A.; Dong, L.; Marakovits, J.; Tikhe, J.; Richardson, P.; Guo, L. C.; Kania, R.; Edwards, M. P.; Kraynov, E.; Christensen, J.; Piraino, J.; Lee, J.; Dagostino, E.; Del-Carmen, C.; Deng, Y.-L.; Smeal, T.; Murray, B. W. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. J. Med. Chem. 2012, 55 (10), 4728-4739.
15. Brodney, M. A. Pyridyl piperazines and Their Preparation and Pharmaceutical Compositions, for the Treatment of CNS Disorders or Conditions That Can Be Treated by Serotonin-Mediated Neuro-transmission. PCT Int. Appl., 2006000912, 2006.
16. Gandon, V.; Bertus, P.; Szymoniak, J. A straightforward synthesis of cyclopropanes from aldehydes and ketones. Eur. J. Org. Chem. 2000, 22, 3713-3719.
17. Nader, B. S.; Cordova, J. A.; Reese, K. E.; Powell, C. L. A Novel Fluoride Ion Mediated Olefination of Electron-Deficient Aryl Ketones by Alkanesulfonyl Halides. J. Org. Chem. 1994, 59 (10), 2898-2901.
18. Phillion, D. P.; Cleary, D. G. Disodium salt of 2-[(dihydroxyphosphinyl) difluoromethyl]propenoic acid: an isopolar and isosteric analog of phosphoenolpyruvate. J. Org. Chem. 1992, 57 (9), 2763-2764.
19. Banks, B. J. Preparation of 1-aryl-4-cyclopropylpyrazoles as medical and agrochemical parasiticides and pesticides. EP 0933363, 1999. Safety note: diazomethane is an explosion hazard.